iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Shares Sold by Winfield Associates Inc.

Winfield Associates Inc. decreased its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 1.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 25,040 shares of the financial services provider’s stock after selling 310 shares during the period. iShares Nasdaq Biotechnology ETF comprises about 1.5% of Winfield Associates Inc.’s investment portfolio, making the stock its 13th biggest holding. Winfield Associates Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $4,048,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IBB. BNP Paribas Arbitrage SA grew its holdings in iShares Nasdaq Biotechnology ETF by 15.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,804,930 shares of the financial services provider’s stock valued at $295,377,000 after buying an additional 241,516 shares during the last quarter. Wells Fargo & Company MN grew its holdings in iShares Nasdaq Biotechnology ETF by 0.6% in the 2nd quarter. Wells Fargo & Company MN now owns 696,627 shares of the financial services provider’s stock valued at $114,002,000 after buying an additional 4,143 shares during the last quarter. Ergoteles LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 483.9% in the 2nd quarter. Ergoteles LLC now owns 606,839 shares of the financial services provider’s stock worth $99,309,000 after acquiring an additional 502,916 shares during the period. Liberty Wealth Management LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 16,275.9% in the 2nd quarter. Liberty Wealth Management LLC now owns 591,006 shares of the financial services provider’s stock worth $3,611,000 after acquiring an additional 587,397 shares during the period. Finally, Commerce Bank lifted its position in shares of iShares Nasdaq Biotechnology ETF by 1.6% in the 2nd quarter. Commerce Bank now owns 576,024 shares of the financial services provider’s stock worth $94,266,000 after acquiring an additional 9,212 shares during the period. 72.28% of the stock is owned by hedge funds and other institutional investors.

Shares of iShares Nasdaq Biotechnology ETF stock traded up $0.39 during midday trading on Thursday, hitting $153.40. 1,445,519 shares of the company were exchanged, compared to its average volume of 2,904,636. iShares Nasdaq Biotechnology ETF has a 52 week low of $138.34 and a 52 week high of $177.37. The firm has a 50 day simple moving average of $159.38 and a 200-day simple moving average of $161.69.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 30th. Investors of record on Monday, September 27th were issued a dividend of $0.124 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.32%. This is a boost from iShares Nasdaq Biotechnology ETF’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend was Friday, September 24th.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: What are the benefits of a portfolio tracker?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.